Jeff Fineman, MD

Education
2021 - Diversity, Equity, Inclusion Champion Training, UCSF
06/1990 - Pediatric Critical Care Fellowship, UCSF
06/1988 - Pediatric Chief Resident, NYU/Bellevue
06/1987 - Pediatric Residency, NYU/Bellevue
MD, 06/1984 - Medicine, New York University School of Medicine
Websites
Publications
  1. Caveolin-1 associated with severe (pediatric-onset) presentation of pulmonary arterial hypertension.
  2. Cardiac Catheterization and Hemodynamics in a Multicenter Cohort of Children with Pulmonary Hypertension.
  3. Progress in Pulmonary Vein Stenosis: Lessons from Success in Treating Pulmonary Arterial Hypertension.
  4. Defining longer term outcomes in an ovine model of moderate perinatal hypoxia-ischemia.
  5. Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension.
  6. Building a dedicated pediatric pulmonary hypertension program: A consensus statement from the pediatric pulmonary hypertension network.
  7. Genetics dictating therapeutic decisions in pediatric pulmonary hypertension? A case report suggesting we are getting closer.
  8. Characterisation of Pediatric Pulmonary Hypertensive Vascular Disease from the PPHNet Registry.
  9. Advanced Microparticulate/Nanoparticulate Respirable Dry Powders of a Selective RhoA/Rho Kinase (Rock) Inhibitor for Targeted Pulmonary Inhalation Aerosol Delivery.
  10. Insights into the impact of sections and departments on your career: The APS-SPR Virtual Chat Series.
  11. Biallelic variants of ATP13A3 cause dose-dependent childhood-onset pulmonary arterial hypertension characterised by extreme morbidity and mortality.
  12. Mortality from Pulmonary Hypertension in the Pediatric Cardiac Intensive Care Unit.
  13. Safety and Tolerability of a Rapid Transition From Intravenous Treprostinil to Oral Selexipag in Three Adolescent Patients With Pulmonary Arterial Hypertension.
  14. Monitoring deep-tissue oxygenation with a millimeter-scale ultrasonic implant.
  15. Pulmonary Arteriovenous Malformations and the Hepatic "Black Box": Are We Emerging From the Darkness?
  16. Practice patterns of pulmonary hypertension secondary to left heart disease among pediatric pulmonary hypertension providers.
  17. Comparison of l-Carnitine and l-Carnitine HCL salt for targeted lung treatment of pulmonary hypertension (PH) as inhalation aerosols: Design, comprehensive characterization, in vitro 2D/3D cell cultures, and in vivo MCT-Rat model of PH.
  18. HIF-1a promotes cellular growth in lymphatic endothelial cells exposed to chronically elevated pulmonary lymph flow.
  19. Advanced therapeutic inhalation aerosols of a Nrf2 activator and RhoA/Rho kinase (ROCK) inhibitor for targeted pulmonary drug delivery in pulmonary hypertension: design, characterization, aerosolization, in vitro 2D/3D human lung cell cultures, and in viv
  20. Arginine recycling in endothelial cells is regulated BY HSP90 and the ubiquitin proteasome system.
  21. Novel Documentation of Onset and Rapid Advancement of Pulmonary Arterial Hypertension without Symptoms in BMPR2 Mutation Carriers: Cautionary Tales?
  22. Inhalable Nanoparticles/Microparticles of an AMPK and Nrf2 Activator for Targeted Pulmonary Drug Delivery as Dry Powder Inhalers.
  23. Activation of the mechanosensitive Ca2+ channel TRPV4 induces endothelial barrier permeability via the disruption of mitochondrial bioenergetics.
  24. Complex interplay between autophagy and oxidative stress in the development of pulmonary disease.
  25. Pharmacokinetics of Oral Treprostinil in Children With Pulmonary Arterial Hypertension.
  26. The many faces and outcomes of pulmonary vein stenosis in early childhood.
  27. Equipoise and Acumen in Pediatric Acute Respiratory Distress Syndrome Research.
  28. TGF-ß1 attenuates mitochondrial bioenergetics in pulmonary arterial endothelial cells via the disruption of carnitine homeostasis.
  29. Mechanical forces alter endothelin-1 signaling: comparative ovine models of congenital heart disease.
  30. Extracorporeal Membrane Oxygenation in Pediatric Pulmonary Hypertension.
  31. Clinical Utility of Echocardiography in Former Preterm Infants with Bronchopulmonary Dysplasia.
  32. Outcomes of pulmonary vascular disease in infants conceived with non-IVF fertility treatment and assisted reproductive technologies at 1 year of age.
  33. Oral treprostinil in transition or as add-on therapy in pediatric pulmonary arterial hypertension.
  34. EXPRESS: Acute Vasoreactivity Testing in Pediatric Idiopathic Pulmonary Arterial Hypertension: an international Survey on Current Practice.
  35. Ovine Models of Congenital Heart Disease and the Consequences of Hemodynamic Alterations for Pulmonary Artery Remodeling.
  36. Pulmonary Endothelial Mechanical Sensing and Signaling, a Story of Focal Adhesions and Integrins in Ventilator Induced Lung Injury.
  37. Mortality in infants with bronchopulmonary dysplasia: Data from cardiac catheterization.
  38. Biomechanical Forces and Oxidative Stress: Implications for Pulmonary Vascular Disease.
  39. Correction: Preservation of myocardial contractility during acute hypoxia with OMX-CV, a novel oxygen delivery biotherapeutic.
  40. Two patients with FOXF1 mutations with alveolar capillary dysplasia with misalignment of pulmonary veins and other malformations: Two different presentations and outcomes.
  41. Preservation of myocardial contractility during acute hypoxia with OMX-CV, a novel oxygen delivery biotherapeutic.
  42. Intensive Care Mortality Prognostic Model for Pediatric Pulmonary Hypertension.
  43. Enhancing the Development and Retention of Physician-Scientists in Academic Pediatrics: Strategies for Success.
  44. Analysis of the microRNA signature driving adaptive right ventricular hypertrophy in an ovine model of congenital heart disease.
  45. KLF2-mediated disruption of PPAR-? signaling in lymphatic endothelial cells exposed to chronically increased pulmonary lymph flow.
  46. The Left Ventricle in Congenital Diaphragmatic Hernia: Implications for the Management of Pulmonary Hypertension.
  47. Safety, efficacy and Management of subcutaneous treprostinil infusions in the treatment of severe pediatric pulmonary hypertension.
  48. Multicenter mortality and morbidity associated with pulmonary hypertension in the pediatric intensive care unit.
  49. Altered Carnitine Homeostasis in Children With Increased Pulmonary Blood Flow Due to Ventricular Septal Defects.
  50. Pulmonary veno-occlusive disease in a pediatric hematopoietic stem cell transplant patient: a cautionary tale.
  51. Pushing the envelope: a treat and repair strategy for patients with advanced pulmonary hypertension associated with congenital heart disease.
  52. Evaluation and Management of Pulmonary Hypertension in Children with Bronchopulmonary Dysplasia.
  53. Pulmonary vein stenosis of ex-premature infants with pulmonary hypertension and bronchopulmonary dysplasia, epidemiology, and survival from a multicenter cohort.
  54. The Prescient Prognosticator? Hepatoma-derived Growth Factor in Pulmonary Hypertension.
  55. Pulmonary artery smooth muscle cell hyperproliferation and metabolic shift triggered by pulmonary overcirculation.
  56. Bosentan as Adjunctive Therapy for Persistent Pulmonary Hypertension of the Newborn: Results of the Randomized Multicenter Placebo-Controlled Exploratory Trial.
  57. Asymmetric Dimethylarginine Stimulates Akt1 Phosphorylation via Heat Shock Protein 70-Facilitated Carboxyl-Terminal Modulator Protein Degradation in Pulmonary Arterial Endothelial Cells.
  58. Pulmonary Hypertension.
  59. Disrupted NOS signaling in lymphatic endothelial cells exposed to chronically increased pulmonary lymph flow.
  60. Metabolic Changes Precede the Development of Pulmonary Hypertension in the Monocrotaline Exposed Rat Lung.
  61. Change in Pediatric Functional Classification During Treatment and Morbidity and Mortality in Children with Pulmonary Hypertension.
  62. Overexpression of Nitric Oxide Synthase Restores Circulating Angiogenic Cell Function in Patients With Coronary Artery Disease: Implications for Autologous Cell Therapy for Myocardial Infarction.
  63. Recommendations for the Use of Inhaled Nitric Oxide Therapy in Premature Newborns with Severe Pulmonary Hypertension.
  64. Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society.
  65. Matrix Remodeling Promotes Pulmonary Hypertension through Feedback Mechanoactivation of the YAP/TAZ-miR-130/301 Circuit.
  66. Complex I dysfunction underlies the glycolytic switch in pulmonary hypertensive smooth muscle cells.
  67. Short-Term Treprostinil Use in Infants with Congenital Diaphragmatic Hernia following Repair.
  68. Right ventricular nitric oxide signaling in an ovine model of congenital heart disease: a preserved fetal phenotype.
  69. Longitudinal development of obesity in the post-Fontan population.
  70. Sox18 preserves the pulmonary endothelial barrier under conditions of increased shear stress.
  71. B-type natriuretic peptide: prognostic marker in congenital diaphragmatic hernia.
  72. Are preoperative B-type natriuretic peptide levels associated with outcome after pulmonary artery banding and the double switch operation in patients with congenitally corrected transposition of the great arteries: a pilot study.
  73. Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension.
  74. Endothelin-1 induces a glycolytic switch in pulmonary arterial endothelial cells via the mitochondrial translocation of endothelial nitric oxide synthase.
  75. Adaptive right ventricular performance in response to acutely increased afterload in a lamb model of congenital heart disease: evidence for enhanced Anrep effect.
  76. Altered reactivity and nitric oxide signaling in the isolated thoracic duct from an ovine model of congenital heart disease with increased pulmonary blood flow.
  77. Nitration of tyrosine 247 inhibits protein kinase G-1a activity by attenuating cyclic guanosine monophosphate binding.
  78. Endothelin-1 stimulates catalase activity through the PKCd-mediated phosphorylation of serine 167.
  79. Antenatal maternally-administered phosphodiesterase type 5 inhibitors normalize eNOS expression in the fetal lamb model of congenital diaphragmatic hernia.
  80. Preoperative B-type natriuretic peptide levels are associated with outcome after total cavopulmonary connection (Fontan).
  81. Reactive oxygen species in pulmonary vascular remodeling.
  82. Reply to the editor.
  83. L-carnitine preserves endothelial function in a lamb model of increased pulmonary blood flow.
  84. The effect of preoperative nutritional status on postoperative outcomes in children undergoing surgery for congenital heart defects in San Francisco (UCSF) and Guatemala City (UNICAR).
  85. Disruption of endothelial cell mitochondrial bioenergetics in lambs with increased pulmonary blood flow.
  86. Differential responses of the right ventricle to abnormal loading conditions in vivo: possible pathophysiologic mechanisms.
  87. Tezosentan increases nitric oxide signaling via enhanced hydrogen peroxide generation in lambs with surgically induced acute increases in pulmonary blood flow.
  88. Chronic inhibition of PPAR-? signaling induces endothelial dysfunction in the juvenile lamb.
  89. Implications of the U.S. Food and Drug Administration warning against the use of sildenafil for the treatment of pediatric pulmonary hypertension.
  90. Rosiglitazone preserves pulmonary vascular function in lambs with increased pulmonary blood flow.
  91. Endostatin, an inhibitor of angiogenesis, decreases after bidirectional superior cavopulmonary anastamosis.
  92. PPAR-? regulates carnitine homeostasis and mitochondrial function in a lamb model of increased pulmonary blood flow.
  93. B-type natriuretic peptide levels predict outcomes in infants undergoing cardiac surgery in a lesion-dependent fashion.
  94. Pulmonary interstitial glycogenosis: an unrecognized etiology of persistent pulmonary hypertension of the newborn in congenital heart disease?
  95. Preserving mitochondrial function prevents the proteasomal degradation of GTP cyclohydrolase I.
  96. Racial disparities in congenital heart disease: beyond red and blue.
  97. Altered lymphatics in an ovine model of congenital heart disease with increased pulmonary blood flow.
  98. Usefulness of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide as biomarkers for heart failure in young children with single ventricle congenital heart disease.
  99. Attenuated vasodilatation in lambs with endogenous and exogenous activation of cGMP signaling: role of protein kinase G nitration.
  100. Advances in the management of pediatric pulmonary hypertension.
  101. Pediatric pulmonary arterial hypertension: current and emerging therapeutic options.
  102. Early determinants of pulmonary vascular remodeling in animal models of complex congenital heart disease.
  103. Delineating the angiogenic gene expression profile before pulmonary vascular remodeling in a lamb model of congenital heart disease.
  104. Oxidative stress and the development of endothelial dysfunction in congenital heart disease with increased pulmonary blood flow: lessons from the neonatal lamb.
  105. Reciprocal regulation of Rac1 and PAK-1 by HIF-1alpha: a positive-feedback loop promoting pulmonary vascular remodeling.
  106. Congenital diaphragmatic hernia: endothelin-1, pulmonary hypertension, and disease severity.
  107. Nitric oxide alterations following acute ductal constriction in the fetal lamb: a role for superoxide.
  108. Perinatal changes in superoxide generation in the ovine lung: Alterations associated with increased pulmonary blood flow.
  109. Mass spectroscopy and molecular modeling predict endothelial nitric oxide synthase dimer collapse by hydrogen peroxide through zinc tetrathiolate metal-binding site disruption.
  110. Early elevations in B-type natriuretic peptide levels are associated with poor clinical outcomes in pediatric acute lung injury.
  111. Usefulness of various plasma biomarkers for diagnosis of heart failure in children with single ventricle physiology.
  112. Effect of PPARgamma inhibition on pulmonary endothelial cell gene expression: gene profiling in pulmonary hypertension.
  113. Alterations in lung arginine metabolism in lambs with pulmonary hypertension associated with increased pulmonary blood flow.
  114. Peripheral arterial function in infants and young children with one-ventricle physiology and hypoxemia.
  115. Progressive dysfunction of nitric oxide synthase in a lamb model of chronically increased pulmonary blood flow: a role for oxidative stress.
  116. Perioperative B-type natriuretic peptide levels predict outcome after bidirectional cavopulmonary anastomosis and total cavopulmonary connection.
  117. Altered carnitine homeostasis is associated with decreased mitochondrial function and altered nitric oxide signaling in lambs with pulmonary hypertension.
  118. Alterations in cGMP, soluble guanylate cyclase, phosphodiesterase 5, and B-type natriuretic peptide induced by chronic increased pulmonary blood flow in lambs.
  119. B-type natriuretic peptide levels predict outcomes for children on extracorporeal life support after cardiac surgery.
  120. B-type natriuretic peptide levels predict outcome after neonatal cardiac surgery.
  121. Nitric oxide and superoxide generation from endothelial NOS: modulation by HSP90.
  122. Lung antioxidant enzymes are regulated by development and increased pulmonary blood flow.
  123. The role of nitric oxide synthase-derived reactive oxygen species in the altered relaxation of pulmonary arteries from lambs with increased pulmonary blood flow.
  124. Fibroblast growth factor-2 expression is altered in lambs with increased pulmonary blood flow and pulmonary hypertension.
  125. Pediatric pulmonary hypertension: Roles of endothelin-1 and nitric oxide.
  126. Abnormal vascular tone in infants and children with lung hypoplasia: Findings from cardiac catheterization and the response to chronic therapy.
  127. Myocardial transcription factors are modulated during pathologic cardiac hypertrophy in vivo.
  128. Nesiritide acutely increases pulmonary and systemic levels of nitric oxide in patients with pulmonary hypertension.
  129. Oxidative and nitrosative stress in pediatric pulmonary hypertension: roles of endothelin-1 and nitric oxide.
  130. BNP for pediatrics--not quite ready for primetime.
  131. Increased oxidative stress in lambs with increased pulmonary blood flow and pulmonary hypertension: role of NADPH oxidase and endothelial NO synthase.
  132. Sp3 inhibits Sp1-mediated activation of the cardiac troponin T promoter and is downregulated during pathological cardiac hypertrophy in vivo.
  133. Alterations in plasma B-type natriuretic peptide levels after repair of congenital heart defects: a potential perioperative marker.
  134. Nitric oxide-endothelin-1 interactions after surgically induced acute increases in pulmonary blood flow in intact lambs.
  135. Inhaled nitric oxide induced NOS inhibition and rebound pulmonary hypertension: a role for superoxide and peroxynitrite in the intact lamb.
  136. Divergent transcriptional enhancer factor-1 regulates the cardiac troponin T promoter.
  137. Endothelin-1 in congenital heart disease.
  138. Nitric oxide decreases surfactant protein gene expression in primary cultures of type II pneumocytes.
  139. Tezosentan, a combined parenteral endothelin receptor antagonist, produces pulmonary vasodilation in lambs with acute and chronic pulmonary hypertension.
  140. Endothelial alterations during inhaled NO in lambs with pulmonary hypertension: implications for rebound hypertension.
  141. Chronic endothelin A receptor blockade in lambs with increased pulmonary blood flow and pressure.
  142. Impact of right ventricle to pulmonary artery conduit on outcome of the modified Norwood procedure.
  143. Inhaled nitric oxide decreases pulmonary soluble guanylate cyclase protein levels in 1-month-old lambs.
  144. Phosphodiesterase-3 inhibition prevents the increase in pulmonary vascular resistance following inhaled nitric oxide withdrawal in lambs.
  145. Treatment of rebound and chronic pulmonary hypertension with oral sildenafil in an infant with congenital diaphragmatic hernia.
  146. Increased pulmonary blood flow does not alter surfactant protein gene expression in lambs within the first week of life.
  147. Pharmacologic therapy for persistent pulmonary hypertension of the newborn: as "poly" as the disease itself.
  148. Emergence of smooth muscle cell endothelin B-mediated vasoconstriction in lambs with experimental congenital heart disease and increased pulmonary blood flow.
  149. Inhaled nitric oxide increases surfactant protein gene expression in the intact lamb.
  150. Alterations in TGF-beta1 expression in lambs with increased pulmonary blood flow and pulmonary hypertension.
  151. Expression of VEGF and its receptors Flt-1 and Flk-1/KDR is altered in lambs with increased pulmonary blood flow and pulmonary hypertension.
  152. Developmental differences in the shear stress-induced expression of endothelial NO synthase: changing role of AP-1.
  153. Alterations in ET-1, not nitric oxide, in 1-week-old lambs with increased pulmonary blood flow.
  154. Pulmonary vascular K+ channel expression and vasoreactivity in a model of congenital heart disease.
  155. Alterations in nitric oxide production in 8-week-old lambs with increased pulmonary blood flow.
  156. Nitric oxide-endothelin-1 interactions after acute ductal constriction in fetal lambs.
  157. Decreased surfactant proteins in lambs with pulmonary hypertension secondary to increased blood flow.
  158. sGC and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hypertension.
  159. Role for endothelin-1-induced superoxide and peroxynitrite production in rebound pulmonary hypertension associated with inhaled nitric oxide therapy.
  160. Inhaled nitric oxide-induced rebound pulmonary hypertension: role for endothelin-1.
  161. Inhaled nitric oxide in neonates with persistent pulmonary hypertension.
  162. Altered endothelium-dependent relaxations in lambs with high pulmonary blood flow and pulmonary hypertension.
  163. Alterations in endogenous nitric oxide production after cardiopulmonary bypass in lambs with normal and increased pulmonary blood flow.
  164. Transthoracic intracardiac catheters in pediatric patients recovering from congenital heart defect surgery: associated complications and outcomes.
  165. Management and outcomes of delayed sternal closure after cardiac surgery in neonates and infants.
  166. Pulmonary blood flow alters nitric oxide production in patients undergoing device closure of atrial septal defects.
  167. Altered regulation of the ET-1 cascade in lambs with increased pulmonary blood flow and pulmonary hypertension.
  168. Inhaled nitric oxide inhibits NOS activity in lambs: potential mechanism for rebound pulmonary hypertension.
  169. The pathophysiology of pulmonary hypertension in congenital heart disease.
  170. Alveolar capillary dysplasia: diagnostic potential for cardiac catheterization.
  171. Inhaled nitric oxide, oxygen, and alkalosis: dose-response interactions in a lamb model of pulmonary hypertension.
  172. Altered endothelial function in lambs with pulmonary hypertension and acute lung injury.
  173. Endothelin receptor blockade prevents the rise in pulmonary vascular resistance after cardiopulmonary bypass in lambs with increased pulmonary blood flow.
  174. Role of the endothelium in placental dysfunction after fetal cardiac bypass.
  175. Endothelin-receptor blockade does not alter closure of the ductus arteriosus.
  176. Increased endothelial NOS in lambs with increased pulmonary blood flow and pulmonary hypertension.
  177. Increased pulmonary blood flow alters the molecular regulation of vascular reactivity in the lamb.
  178. The effects of inhaled nitric oxide on postoperative pulmonary hypertension in infants and children undergoing surgical repair of congenital heart disease.
  179. Models of persistent pulmonary hypertension of the newborn (PPHN) and the role of cyclic guanosine monophosphate (GMP) in pulmonary vasorelaxation.
  180. Inhaled nitric oxide enhances oxygenation but not survival in infants with alveolar capillary dysplasia.
  181. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group.
  182. Post-cardiopulmonary bypass pulmonary hypertension in lambs with increased pulmonary blood flow. A role for endothelin 1.
  183. Hemodynamic effects of epinephrine, bicarbonate and calcium in the early postnatal period in a lamb model of single-ventricle physiology created in utero.
  184. Altered endothelium-dependent responses in lambs with pulmonary hypertension and increased pulmonary blood flow.
  185. Exogenous endothelin-1 causes renal vasodilation in the fetal lamb.
  186. Fetal model of single ventricle physiology: hemodynamic effects of oxygen, nitric oxide, carbon dioxide, and hypoxia in the early postnatal period.
  187. Endothelin receptor blockade does not alter the increase in pulmonary blood flow due to oxygen ventilation in fetal lambs.
  188. Invited editorial on "Antenatal betamethasone therapy augments nitric oxide-mediated relaxation of preterm ovine pulmonary veins".
  189. Endothelin-1 vasoactive responses in lambs with pulmonary hypertension and increased pulmonary blood flow.
  190. In utero placement of aortopulmonary shunts. A model of postnatal pulmonary hypertension with increased pulmonary blood flow in lambs.
  191. Inhaled nitric oxide therapy for persistent pulmonary hypertension of the newborn.
  192. Endothelinb receptor agonists produce pulmonary vasodilation in intact newborn lambs with pulmonary hypertension.
  193. Regulation of pulmonary vascular tone in the perinatal period.
  194. Inhaled nitric oxide in congenital hypoplasia of the lungs due to diaphragmatic hernia or oligohydramnios.
  195. Developmental effects of endothelin-1 on the pulmonary circulation in sheep.
  196. Use of ATP-MgCl2 in the evaluation and treatment of children with pulmonary hypertension secondary to congenital heart defects.
  197. Chronic nitric oxide inhibition in utero produces persistent pulmonary hypertension in newborn lambs.
  198. The role of endothelin and endothelin receptor subtypes in regulation of fetal pulmonary vascular tone.
  199. HA1004, an intracellular calcium antagonist, selectively attenuates pulmonary hypertension in newborn lambs.
  200. Diethylamine/nitric oxide (NO) adduct, an NO donor, produces potent pulmonary and systemic vasodilation in intact newborn lambs.
  201. Endothelin-1 produces pulmonary vasodilation in the intact newborn lamb.
  202. Hyperoxia and alkalosis produce pulmonary vasodilation independent of endothelium-derived nitric oxide in newborn lambs.
  203. Endothelin-1 does not mediate acute hypoxic pulmonary vasoconstriction in the intact newborn lamb.
  204. M&B 22948, a cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs.
  205. EDRF inhibition attenuates the increase in pulmonary blood flow due to oxygen ventilation in fetal lambs.
  206. K+ channel pulmonary vasodilation in fetal lambs: role of endothelium-derived nitric oxide.
  207. EDRF inhibition augments pulmonary hypertension in intact newborn lambs.
  208. L-Arginine, a precursor of EDRF in vitro, produces pulmonary vasodilation in lambs.
  209. In vivo attenuation of endothelium-dependent pulmonary vasodilation by methylene blue.
  210. N omega-nitro-L-arginine attenuates endothelium-dependent pulmonary vasodilation in lambs.
  211. Effects of vasoactive drugs on thromboxane A2 mimetic-induced pulmonary hypertension in newborn lambs.
  212. The role of pulmonary vascular endothelium in perinatal pulmonary circulatory regulation.
  213. Selective pulmonary vasodilation with ATP-MgCl2 during pulmonary hypertension in lambs.